Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses CHRS in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named CHRS in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Dennis Lanfear | $1,026,545 | $0 | $0 | $828,130 | $869,295 | $0 | $12,904 | $2,736,874 |
| President, Chief Executive Officer and Chairman of the Board of Directors | ||||||||
| Paul Reider | 217,742 | 0 | 0 | 347,760 | 0 | 0 | 662,022 | 1,227,524 |
| Former Chief Commercial Officer | ||||||||
| Bryan McMichael | 543,688 | 0 | 0 | 314,192 | 237,697 | 0 | 7,500 | 1,103,077 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Dennis Lanfear | $2,736,874 | $4,802,309 | — | −2,065,435 |
| Paul Reider | 1,227,524 | 1,657,415 | — | −429,891 |
| Bryan McMichael | 1,103,077 | 1,032,870 | — | +70,207 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Bryan McMichael | Chief Financial Officer | 2026-05-29 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis M. Lanfear | Director | 2026-05-29 | A | 125,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bryan McMichael | Chief Financial Officer | 2026-05-29 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis M. Lanfear | Director | 2026-05-29 | D | 500,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bryan McMichael | Chief Financial Officer | 2026-05-29 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bryan McMichael | Chief Financial Officer | 2026-05-29 | A | 100,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bryan McMichael | Chief Financial Officer | 2026-05-29 | A | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bryan McMichael | Chief Financial Officer | 2026-05-29 | A | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis M. Lanfear | Director | 2026-05-29 | D | 400,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis M. Lanfear | Director | 2026-05-29 | D | 402,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis M. Lanfear | Director | 2026-05-29 | D | 402,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis M. Lanfear | Director | 2026-05-29 | A | 400,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis M. Lanfear | Director | 2026-05-29 | A | 500,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis M. Lanfear | Director | 2026-05-29 | A | 402,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bryan McMichael | Chief Financial Officer | 2026-05-29 | A | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bryan McMichael | Chief Financial Officer | 2026-05-29 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bryan McMichael | Chief Financial Officer | 2026-05-29 | A | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis M. Lanfear | Director | 2026-05-29 | D | 125,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bryan McMichael | Chief Financial Officer | 2026-05-29 | D | 100,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis M. Lanfear | Director | 2026-05-29 | D | 225,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis M. Lanfear | Director | 2026-05-29 | A | 200,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis M. Lanfear | Director | 2026-05-29 | A | 500,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis M. Lanfear | Director | 2026-05-29 | A | 402,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis M. Lanfear | Director | 2026-05-29 | A | 225,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bryan McMichael | Chief Financial Officer | 2026-05-29 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bryan McMichael | Chief Financial Officer | 2026-05-29 | A | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis M. Lanfear | Director | 2026-05-29 | D | 200,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis M. Lanfear | Director | 2026-05-29 | D | 450,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis M. Lanfear | Director | 2026-05-29 | D | 500,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis M. Lanfear | Director | 2026-05-29 | A | 450,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles W. Newton | Director | 2026-06-05 | A | 30,000 | 0 | 0 | Common | Form 4 ↗ |
| Charles W. Newton | Director | 2026-06-05 | A | 60,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lee N. Newcomer, MD | Director | 2026-06-05 | A | 60,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rita A. Karachun | Director | 2026-06-05 | A | 60,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ali J. Satvat | Director | 2026-06-05 | A | 30,000 | 0 | 0 | Common | Form 4 ↗ |
| Lee N. Newcomer, MD | Director | 2026-06-05 | A | 30,000 | 0 | 0 | Common | Form 4 ↗ |
| Michael Ryan | Director | 2026-06-05 | A | 60,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jill O'Donnell-Tormey | Director | 2026-06-05 | A | 60,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mats Wahlstrom | Director | 2026-06-05 | A | 30,000 | 0 | 0 | Common | Form 4 ↗ |
| Ali J. Satvat | Director | 2026-06-05 | A | 60,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rita A. Karachun | Director | 2026-06-05 | A | 30,000 | 0 | 0 | Common | Form 4 ↗ |
| Michael Ryan | Director | 2026-06-05 | A | 30,000 | 0 | 0 | Common | Form 4 ↗ |
| Jill O'Donnell-Tormey | Director | 2026-06-05 | A | 30,000 | 0 | 0 | Common | Form 4 ↗ |
| Mats Wahlstrom | Director | 2026-06-05 | A | 60,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Bryan McMichael | OPTION | — | — | — | — | — | $314,192 |
| Dennis Lanfear | OPTION | — | — | — | — | — | 828,130 |
| Paul Reider | OPTION | — | — | — | — | — | 347,760 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Bryan McMichael | $0 | $0 | $314,192 | 0.0% |
| Dennis Lanfear | 0 | 0 | 828,130 | 0.0% |
| Paul Reider | 0 | 0 | 347,760 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Bryan McMichael | RSU | 4,166 | — | $5,916 |
| Bryan McMichael | RSU | 316,250 | — | 316,250 |
| Dennis Lanfear | Option | 8,386 | 15.94 | — |
| Paul Reider | Option | 782 | 15.94 | — |
| Dennis Lanfear | RSU | 316,250 | — | 316,250 |
| Dennis Lanfear | RSU | 28,750 | — | 40,825 |
| Bryan McMichael | Option | 50,000 | 1.24 | — |
| Dennis Lanfear | Option | 575,000 | 1.47 | — |
| Dennis Lanfear | Option | 109,011 | 10.37 | — |
| Bryan McMichael | Option | 521 | 14.67 | — |
| Bryan McMichael | Option | 6,771 | 9.87 | — |
| Bryan McMichael | Option | 7,813 | 6 | — |
| Bryan McMichael | Option | 65,105 | 3.14 | — |
| Dennis Lanfear | Option | 375,000 | 0.95 | — |
| Bryan McMichael | Option | 200,000 | 0.95 | — |
| Paul Reider | Option | 83,334 | 3.14 | — |
| Paul Reider | Option | 160,000 | 1.66 | — |
| Dennis Lanfear | SAR | 4,191,904 | 3.64 | — |
| Paul Reider | SAR | 6,889,868 | 7.22 | — |
| Bryan McMichael | RSU | 133,736 | — | 430,934 |
| Paul Reider | RSU | 78,636 | — | 111,664 |
| Bryan McMichael | Option | 160,000 | 1.66 | — |
| Paul Reider | RSU | 13,333 | — | 18,933 |
| Dennis Lanfear | Option | 299,480 | 3.14 | — |
| Bryan McMichael | Option | 2,813 | 10.78 | — |
| Paul Reider | Option | 21,667 | 9.87 | — |
The key objective in our executive compensation program is to attract, motivate and reward leaders with the skills and experience necessary to successfully execute on our strategic plan to maximize stockholder value.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | True |
| Anti-pledging | false |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-27 | 73,322,772 | 10,862,168 | 4,822,016 | 87.1% | Passed |
| 2025 | 2025-06-11 | 19,179,927 | 16,164,644 | 3,583,400 | 54.27% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-27 | 87.1%a |
| 2025 | 2025-06-11 | 54.27%b |
a. Approved under the standard stated in the filing — “Abstentions will not be counted as votes cast on this proposal.”.
b. Approved under the standard stated in the filing — “Abstentions will not be counted as votes cast on this proposal.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Mats L. WahlströmIndependent · Lead Independent Director · Audit · Nominating/Governance · Strategic Transaction (Chair) | $130,000 | $0 | $61,667 | $0 | $0 | $191,667 |
| Ali J. SatvatIndependent · Audit · Nominating/Governance (Chair) · Strategic Transaction | 82,500 | 0 | 61,667 | 0 | 0 | 144,167 |
| Charles W. NewtonIndependent · Compensation (Chair) · Strategic Transaction | 82,500 | 0 | 61,667 | 0 | 0 | 144,167 |
| Rita A. KarachunIndependent · Audit (Chair) | 77,500 | 0 | 61,667 | 0 | 0 | 139,167 |
| Georgia ErbezIndependent · Audit · Not standing for re-election | 72,500 | 0 | 61,667 | 0 | 0 | 134,167 |
| Michael RyanIndependent · Compensation · Strategic Transaction | 69,375 | 0 | 61,667 | 0 | 0 | 131,042 |
| Lee N. Newcomer, MDIndependent · Compensation | 60,000 | 0 | 61,667 | 0 | 0 | 121,667 |
| Jill O'Donnell-Tormey, Ph.DIndependent · Nominating/Governance | 55,000 | 0 | 61,667 | 0 | 0 | 116,667 |
| Mark D. StolperIndependent · Departed during FY | 35,000 | 0 | 0 | 0 | 0 | 35,000 |
| Dennis M. LanfearEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $61,667 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 10,000 / 20,000 / 5,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $664,375 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $664,375 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Coherus Oncology, Inc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Coherus Oncology, Inc..
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | PTC Therapeutics | 2025 | Matthew Klein | $958,500 | $16,593,800 | $4,399,760 | $1,294,000 | $23,266,326 |
| 2 | Supernus Pharmaceuticals | 2025 | Jack Khattar | 1,036,000 | 6,535,029 | 7,031,545 | 846,930 | 15,501,557 |
| 3 | Corcept Therapeutics | 2025 | Joseph Belanoff | 1,182,333 | 0 | 12,907,718 | 0 | 15,303,551 |
| 4 | Pacira BioSciences | 2025 | Frank Lee | 935,308 | 9,215,500 | 0 | 738,810 | 11,636,917 |
| 5 | Eagle Pharmaceuticals | 2022 | Scott Tarriff | 848,940 | 9,011,197 | 0 | 636,705 | 10,520,577 |
| 6 | Mirum Pharmaceuticals | 2025 | Christopher Peetz | 755,000 | 3,683,904 | 4,931,320 | 1,057,000 | 10,441,224 |
| 7 | Amicus Pharmaceuticals | 2024 | Bradley Campbell | 767,308 | 4,990,365 | 2,105,627 | 0 | 8,526,943 |
| 8 | ACADIA Pharmaceuticals | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 9 | Nektar Therapeutics | 2025 | Howard Robin | 1,106,282 | 942,081 | 2,986,535 | 1,106,282 | 6,256,954 |
| 10 | Allogene Therapeutics | 2025 | David Chang | 724,000 | 2,409,537 | 2,588,329 | 400,010 | 6,136,093 |
| 11 | Deciphera Pharmaceuticals | 2023 | Steven Hoerter | 738,200 | 1,935,000 | 2,837,100 | 487,212 | 6,010,712 |
| 12 | Replimune Group | 2026 | Sushil Patel | 700,000 | 3,376,003 | 1,448,325 | 315,000 | 5,845,982 |
| 13 | Xencor | 2025 | Bassil Dahiyat | 742,800 | 1,552,892 | 2,727,018 | 490,248 | 5,521,205 |
| 14 | Pliant Therapeutics | 2025 | Bernard Coulie | 682,000 | 1,810,250 | 2,713,750 | 204,600 | 5,462,901 |
| 15 | Agios Pharmaceuticals | 2025 | Brian Goff | 846,864 | 1,291,680 | 2,627,252 | 592,804 | 5,370,389 |
| 16 | Precigen | 2025 | Helen Sabzevari | 1,000,000 | 2,215,000 | 1,069,200 | 1,049,997 | 5,354,329 |
| 17 | Cullinan Therapeutics | 2025 | Nadim Ahmed | 698,476 | 1,697,400 | 2,234,340 | 419,086 | 5,100,006 |
| 18 | Lyell Immunopharma | 2025 | Lynn Seely | 690,173 | 186,806 | 2,907,551 | 414,000 | 4,222,265 |
| 19 | Heron Therapeutics | 2025 | Craig Collard | 689,431 | 946,254 | 1,352,917 | 517,189 | 3,516,291 |
| 20 | Olema Pharmaceuticals | 2025 | Sean Bohen | 699,920 | 0 | 2,002,000 | 461,900 | 3,178,990 |
| 21 | Puma Biotechnology | 2025 | Alan Auerbach | 931,333 | 551,549 | 535,513 | 1,027,307 | 3,062,337 |
| 22 | Cardiff Oncology | 2025 | Mark Erlander | 635,000 | 0 | 2,266,106 | 122,238 | 3,023,344 |
| 23 | Coherus Oncology, Inc. | 2025 | Dennis Lanfear | 1,026,545 | 0 | 828,130 | 869,295 | 2,736,874 |
| 24 | Perspective Therapeutics | 2025 | Johan Spoor | 680,000 | 0 | 1,302,692 | 408,000 | 2,404,692 |
| 25 | Karyopharm Therapeutics | 2025 | Richard Paulson | 770,000 | 838,996 | 241,544 | 350,350 | 2,320,902 |
| 26 | Black Diamond Therapeutics | 2025 | Mark Velleca | 667,400 | 189,000 | 1,006,030 | 348,717 | 2,234,919 |
| 27 | Actuate Therapeutics | 2025 | Daniel Schmitt | 570,000 | 0 | 1,454,193 | 0 | 2,166,522 |
| 28 | Ironwood Pharmaceuticals | 2025 | Thomas McCourt | 867,568 | 411,696 | 0 | 650,676 | 1,948,390 |
| 29 | Collegium Pharmaceuticals | 2025 | Vikram Karnani | 875,000 | 0 | 0 | 835,406 | 1,715,846 |
| 30 | Zentalis Pharmaceuticals | 2025 | Julie Eastland | 700,000 | 99,772 | 56,975 | 441,000 | 1,300,731 |
| — | Intercept Pharmaceuticals | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Coherus Oncology, Inc. | not disclosed | Options 100 | not disclosed | Aon |
| ACADIA Pharmaceuticals | 110% | Options 50 · PSU 25 · RSU 25 | Yes | FW Cook |
| Actuate Therapeutics | not disclosed | Options 100 | not disclosed | Anderson Pay Advisors LLC |
| Agios Pharmaceuticals | 100% | Options 40 · PSU 40 · RSU 20 | No | Aon |
| Allogene Therapeutics | 85% | Options 55 · RSU 25 · PSU 20 | No | Compensia |
| Amicus Pharmaceuticals | 108% | Options 33 · RSU 33 · PSU 33 | Yes — TSR Goal | Pay Governance |
| Black Diamond Therapeutics | 95% | not disclosed | not disclosed | Aon Human Capital Solutions (Aon plc) |
| Cardiff Oncology | 35% | Options 100 | not disclosed | Aon |
| Collegium Pharmaceuticals | 127.3% | RSU 70 · PSU 30 | Yes — relative ranking of the total shareholder return (TSR) of the Company's common stock in 2025, 2026, 2027 and the cumulative three-year performance period (2025-2027) return relative to the TSR of peer companies within the S&P Pharmaceutical Select Industry Index | Alpine Rewards, LLC |
| Corcept Therapeutics | 100% | not disclosed | not disclosed | not disclosed |
| Cullinan Therapeutics | not disclosed | not disclosed | not disclosed | Compensia (through June 2025); Pay Governance (since June 2025) |
| Deciphera Pharmaceuticals | 110% | Options 50 · PSU 50 | No | Pearl Meyer & Partners, LLC |
| Eagle Pharmaceuticals | 75% | PSU 75 · RSU 25 | Yes — Total Shareholder Return (TSR) relative to S&P 600 Biotech Select Index (rTSR) | Compensia |
| Heron Therapeutics | 100% | Options 67 · RSU 33 | not disclosed | Compensia, Inc. |
| Intercept Pharmaceuticals | not disclosed | not disclosed | not disclosed | not disclosed |
| Ironwood Pharmaceuticals | 100% | PSU 50 · RSU 50 | Yes — relative total stockholder return (rTSR) | Alpine Rewards LLC |
| Karyopharm Therapeutics | 90% | not disclosed | Yes — Relative TSR | Alpine Rewards, LLC (through September 2025); Willis Towers Watson (beginning August 2025) |
| Lyell Immunopharma | 100% | not disclosed | No | Alpine |
| Mirum Pharmaceuticals | 200% | not disclosed | No | Alpine Rewards |
| Nektar Therapeutics | 100% | not disclosed | No | Aon |
| Olema Pharmaceuticals | 110% | Options 100 | not disclosed | Aon |
| Pacira BioSciences | 90% | RSU 100 | No | Aon (Aon plc, Human Capital Solutions practice) |
| Perspective Therapeutics | not disclosed | Options 100 | not disclosed | Aon |
| Pliant Therapeutics | 50% | Options 67 · RSU 33 | not disclosed | Alpine Rewards |
| Precigen | 140% | not disclosed | not disclosed | Aon |
| PTC Therapeutics | 167% | Options 50 · RSU 50 | Yes — TSR relative to Nasdaq Biotechnology Index | FW Cook |
| Puma Biotechnology | 169.7% | Options 50 · RSU 50 | not disclosed | Compensia |
| Replimune Group | not disclosed | not disclosed | No | Pearl Meyer |
| Supernus Pharmaceuticals | not disclosed | not disclosed | No | Aon plc (Human Capital Solutions practice) |
| Xencor | 110% | Options 60 · RSU 40 | not disclosed | Aon |
| Zentalis Pharmaceuticals | 105% | not disclosed | not disclosed | Anderson Pay Advisors LLC / Pay Governance LLC |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Dennis Lanfear | DEF 14A | 2026-04-20 | 0001104659-26-045251 | Section “Summary Compensation Table”. As printed: 2,736,874. Filing ↗machine: t112 · r5 · c14 · span 540087–540096 |
| 2 | Section 01, Paul Reider | DEF 14A | 2026-04-20 | 0001104659-26-045251 | Section “Summary Compensation Table”. As printed: 1,227,524. Filing ↗machine: t112 · r9 · c14 · span 555128–555137 |
| 3 | Section 01, Bryan McMichael | DEF 14A | 2026-04-20 | 0001104659-26-045251 | Section “Summary Compensation Table”. As printed: 1,103,077. Filing ↗machine: t112 · r7 · c14 · span 547600–547609 |
| 4 | Section 03, Bryan McMichael OPTION | DEF 14A | 2026-04-20 | 0001104659-26-045251 | Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t112 · r7 · c8 · span 546088–546095 |
| 5 | Section 03, Dennis Lanfear OPTION | DEF 14A | 2026-04-20 | 0001104659-26-045251 | Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t112 · r5 · c8 · span 538460–538467 |
| 6 | Section 03, Paul Reider OPTION | DEF 14A | 2026-04-20 | 0001104659-26-045251 | Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t112 · r9 · c8 · span 553505–553512 |
| 7 | Section 07, pay ratio | 10-K | 2026-03-09 | 0001104659-26-025308 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 8 | Section 08, Mats L. Wahlström | DEF 14A | 2026-04-20 | 0001104659-26-045251 | Section “Director Compensation”. As printed: 191,667. Filing ↗machine: t97 · r11 · c6 · span 482127–482134 |
| 9 | Section 08, Ali J. Satvat | DEF 14A | 2026-04-20 | 0001104659-26-045251 | Section “Director Compensation”. As printed: 144,167. Filing ↗machine: t97 · r9 · c6 · span 478126–478133 |
| 10 | Section 08, Charles W. Newton | DEF 14A | 2026-04-20 | 0001104659-26-045251 | Section “Director Compensation”. As printed: 144,167. Filing ↗machine: t97 · r6 · c6 · span 472059–472066 |
| 11 | Section 08, Rita A. Karachun | DEF 14A | 2026-04-20 | 0001104659-26-045251 | Section “Director Compensation”. As printed: 139,167. Filing ↗machine: t97 · r4 · c6 · span 468058–468065 |
| 12 | Section 08, Georgia Erbez | DEF 14A | 2026-04-20 | 0001104659-26-045251 | Section “Director Compensation”. As printed: 134,167. Filing ↗machine: t97 · r3 · c6 · span 466139–466146 |
| 13 | Section 08, Michael Ryan | DEF 14A | 2026-04-20 | 0001104659-26-045251 | Section “Director Compensation”. As printed: 131,042. Filing ↗machine: t97 · r8 · c6 · span 476064–476071 |
| 14 | Section 08, Lee N. Newcomer, MD | DEF 14A | 2026-04-20 | 0001104659-26-045251 | Section “Director Compensation”. As printed: 121,667. Filing ↗machine: t97 · r5 · c6 · span 470126–470133 |
| 15 | Section 08, Jill O'Donnell-Tormey, Ph.D | DEF 14A | 2026-04-20 | 0001104659-26-045251 | Section “Director Compensation”. As printed: 116,667. Filing ↗machine: t97 · r7 · c6 · span 474136–474143 |
| 16 | Section 08, Mark D. Stolper | DEF 14A | 2026-04-20 | 0001104659-26-045251 | Section “Director Compensation”. As printed: 35,000. Filing ↗machine: t97 · r10 · c2 · span 478916–478922 |
| 17 | Section 08, Dennis M. Lanfear | DEF 14A | 2026-04-20 | 0001104659-26-045251 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 18 | Section 02, Bryan McMichael 2026-05-29 | Form 4 | 2026-06-02 | 0001104659-26-069622 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 19 | Section 02, Dennis M. Lanfear 2026-05-29 | Form 4 | 2026-06-02 | 0001104659-26-069621 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 20 | Section 02, Bryan McMichael 2026-05-29 | Form 4 | 2026-06-02 | 0001104659-26-069622 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 21 | Section 02, Dennis M. Lanfear 2026-05-29 | Form 4 | 2026-06-02 | 0001104659-26-069621 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, Bryan McMichael 2026-05-29 | Form 4 | 2026-06-02 | 0001104659-26-069622 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Bryan McMichael 2026-05-29 | Form 4 | 2026-06-02 | 0001104659-26-069622 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Bryan McMichael 2026-05-29 | Form 4 | 2026-06-02 | 0001104659-26-069622 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Bryan McMichael 2026-05-29 | Form 4 | 2026-06-02 | 0001104659-26-069622 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Dennis M. Lanfear 2026-05-29 | Form 4 | 2026-06-02 | 0001104659-26-069621 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Dennis M. Lanfear 2026-05-29 | Form 4 | 2026-06-02 | 0001104659-26-069621 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Dennis M. Lanfear 2026-05-29 | Form 4 | 2026-06-02 | 0001104659-26-069621 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Dennis M. Lanfear 2026-05-29 | Form 4 | 2026-06-02 | 0001104659-26-069621 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Dennis M. Lanfear 2026-05-29 | Form 4 | 2026-06-02 | 0001104659-26-069621 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Dennis M. Lanfear 2026-05-29 | Form 4 | 2026-06-02 | 0001104659-26-069621 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Bryan McMichael 2026-05-29 | Form 4 | 2026-06-02 | 0001104659-26-069622 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Bryan McMichael 2026-05-29 | Form 4 | 2026-06-02 | 0001104659-26-069622 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Bryan McMichael 2026-05-29 | Form 4 | 2026-06-02 | 0001104659-26-069622 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Dennis M. Lanfear 2026-05-29 | Form 4 | 2026-06-02 | 0001104659-26-069621 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Bryan McMichael 2026-05-29 | Form 4 | 2026-06-02 | 0001104659-26-069622 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Dennis M. Lanfear 2026-05-29 | Form 4 | 2026-06-02 | 0001104659-26-069621 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Dennis M. Lanfear 2026-05-29 | Form 4 | 2026-06-02 | 0001104659-26-069621 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Dennis M. Lanfear 2026-05-29 | Form 4 | 2026-06-02 | 0001104659-26-069621 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Dennis M. Lanfear 2026-05-29 | Form 4 | 2026-06-02 | 0001104659-26-069621 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Dennis M. Lanfear 2026-05-29 | Form 4 | 2026-06-02 | 0001104659-26-069621 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Bryan McMichael 2026-05-29 | Form 4 | 2026-06-02 | 0001104659-26-069622 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Bryan McMichael 2026-05-29 | Form 4 | 2026-06-02 | 0001104659-26-069622 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Dennis M. Lanfear 2026-05-29 | Form 4 | 2026-06-02 | 0001104659-26-069621 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Dennis M. Lanfear 2026-05-29 | Form 4 | 2026-06-02 | 0001104659-26-069621 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Dennis M. Lanfear 2026-05-29 | Form 4 | 2026-06-02 | 0001104659-26-069621 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Dennis M. Lanfear 2026-05-29 | Form 4 | 2026-06-02 | 0001104659-26-069621 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Charles W. Newton 2026-06-05 | Form 4 | 2026-06-09 | 0001610717-26-000200 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Charles W. Newton 2026-06-05 | Form 4 | 2026-06-09 | 0001610717-26-000200 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Lee N. Newcomer, MD 2026-06-05 | Form 4 | 2026-06-09 | 0001610717-26-000204 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Rita A. Karachun 2026-06-05 | Form 4 | 2026-06-09 | 0001610717-26-000205 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Ali J. Satvat 2026-06-05 | Form 4 | 2026-06-09 | 0001610717-26-000206 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Lee N. Newcomer, MD 2026-06-05 | Form 4 | 2026-06-09 | 0001610717-26-000204 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Michael Ryan 2026-06-05 | Form 4 | 2026-06-09 | 0001610717-26-000203 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Jill O'Donnell-Tormey 2026-06-05 | Form 4 | 2026-06-09 | 0001610717-26-000202 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Mats Wahlstrom 2026-06-05 | Form 4 | 2026-06-09 | 0001610717-26-000201 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Ali J. Satvat 2026-06-05 | Form 4 | 2026-06-09 | 0001610717-26-000206 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Rita A. Karachun 2026-06-05 | Form 4 | 2026-06-09 | 0001610717-26-000205 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Michael Ryan 2026-06-05 | Form 4 | 2026-06-09 | 0001610717-26-000203 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Jill O'Donnell-Tormey 2026-06-05 | Form 4 | 2026-06-09 | 0001610717-26-000202 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Mats Wahlstrom 2026-06-05 | Form 4 | 2026-06-09 | 0001610717-26-000201 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 06, 2026 vote | Form 8-K | 2026-06-01 | 0001104659-26-068615 | Item 5.07 · say-on-pay result. As reported: 87.1% (votes for as printed: 73,322,772). Filing ↗ |
| 63 | Section 06, 2025 vote | Form 8-K | 2025-06-13 | 0001104659-25-059351 | Item 5.07 · say-on-pay result. As reported: 54.27% (votes for as printed: 19,179,927). Filing ↗ |
| 64 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 65 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 66 | Section 09b board cost (computed) | Computed | — | computed | Cash 664,375 + equity 0 + all other 0 = 664,375, summed across the director compensation table rows.machine: formula: Σ = 664,375 |
| 67 | PTC Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-20 | 0001104659-26-045528 | CEO total compensation as printed in PTC Therapeutics's own proxy. As printed: 23,266,326. Filing ↗machine: t148 · r6 · c16 · span 769400–769410 |
| 68 | Supernus Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001104659-26-053111 | CEO total compensation as printed in Supernus Pharmaceuticals's own proxy. As printed: 15,501,557. Filing ↗machine: r1 · c41 · span 430594–430604 |
| 69 | Corcept Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-17 | 0001628280-26-025735 | CEO total compensation as printed in Corcept Therapeutics's own proxy. As printed: 15,303,551. Filing ↗machine: span 283504–283514 |
| 70 | Pacira BioSciences, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050353 | CEO total compensation as printed in Pacira BioSciences's own proxy. As printed: 11,636,917. Filing ↗machine: t136 · r1 · c47 · span 2412158–2412168 |
| 71 | Eagle Pharmaceuticals, Section 10b CEO total | DEF 14A | 2023-05-01 | 0001104659-23-054338 | CEO total compensation as printed in Eagle Pharmaceuticals's own proxy. As printed: 10,520,577. Filing ↗machine: r1 · c47 · span 689556–689566 |
| 72 | Mirum Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001759425-26-000027 | CEO total compensation as printed in Mirum Pharmaceuticals's own proxy. As printed: 10,441,224. Filing ↗machine: r2 · c21 · span 580200–580210 |
| 73 | Amicus Pharmaceuticals, Section 10b CEO total | DEF 14A | 2025-04-24 | 0001140361-25-015479 | CEO total compensation as printed in Amicus Pharmaceuticals's own proxy. As printed: 8,526,943. Filing ↗machine: r2 · c25 · span 736127–736137 |
| 74 | ACADIA Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-174163 | CEO total compensation as printed in ACADIA Pharmaceuticals's own proxy. As printed: 8,256,518. Filing ↗machine: t33 · span 1170878–1170887 |
| 75 | Nektar Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001140361-26-016708 | CEO total compensation as printed in Nektar Therapeutics's own proxy. As printed: 6,256,954. Filing ↗machine: r2 · c24 · span 738327–738336 |
| 76 | Allogene Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001628280-26-028948 | CEO total compensation as printed in Allogene Therapeutics's own proxy. As printed: 6,136,093. Filing ↗machine: r2 · c54 · span 451014–451023 |
| 77 | Deciphera Pharmaceuticals, Section 10b CEO total | DEF 14A | 2024-04-25 | 0001654151-24-000012 | CEO total compensation as printed in Deciphera Pharmaceuticals's own proxy. As printed: 6,010,712. Filing ↗machine: span 605886–605895 |
| 78 | Replimune Group, Section 10b CEO total | DEF 14A | 2026-07-29 | 0001104659-26-087650 | CEO total compensation as printed in Replimune Group's own proxy. As printed: 5,845,982. Filing ↗machine: r1 · c41 · span 430765–430774 |
| 79 | Xencor, Section 10b CEO total | DEF 14A | 2026-04-27 | 0001326732-26-000031 | CEO total compensation as printed in Xencor's own proxy. As printed: 5,521,205. Filing ↗machine: t32 · r3 · c19 · span 631325–631334 |
| 80 | Pliant Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-22 | 0001746473-26-000076 | CEO total compensation as printed in Pliant Therapeutics's own proxy. As printed: 5,462,901. Filing ↗machine: r2 · c48 · span 436933–436942 |
| 81 | Agios Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177086 | CEO total compensation as printed in Agios Pharmaceuticals's own proxy. As printed: 5,370,389. Filing ↗machine: r2 · c31 · span 613185–613194 |
| 82 | Precigen, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001140361-26-018214 | CEO total compensation as printed in Precigen's own proxy. As printed: 5,354,329. Filing ↗machine: r2 · c24 · span 721439–721448 |
| 83 | Cullinan Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-183465 | CEO total compensation as printed in Cullinan Therapeutics's own proxy. As printed: 5,100,006. Filing ↗machine: r2 · c24 · span 475245–475254 |
| 84 | Lyell Immunopharma, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001140361-26-016686 | CEO total compensation as printed in Lyell Immunopharma's own proxy. As printed: 4,222,265. Filing ↗machine: r2 · c24 · span 450163–450172 |
| 85 | Heron Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001193125-26-196306 | CEO total compensation as printed in Heron Therapeutics's own proxy. As printed: 3,516,291. Filing ↗machine: span 728212–728221 |
| 86 | Olema Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191956 | CEO total compensation as printed in Olema Pharmaceuticals's own proxy. As printed: 3,178,990. Filing ↗machine: t29 · r5 · c16 · span 612371–612380 |
| 87 | Puma Biotechnology, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001437749-26-013671 | CEO total compensation as printed in Puma Biotechnology's own proxy. As printed: 3,062,337. Filing ↗machine: t56 · r1 · c29 · span 540970–540979 |
| 88 | Cardiff Oncology, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001213037-26-000006 | CEO total compensation as printed in Cardiff Oncology's own proxy. As printed: 3,023,344. Filing ↗machine: r2 · c16 · span 873925–873934 |
| 89 | Coherus Oncology, Inc. (subject), Section 10b CEO total | DEF 14A | 2026-04-20 | 0001104659-26-045251 | CEO total compensation as printed in Coherus Oncology, Inc.'s own proxy. As printed: 2,736,874. Filing ↗machine: t112 · r5 · c14 · span 540087–540096 |
| 90 | Perspective Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-16 | 0001193125-26-159005 | CEO total compensation as printed in Perspective Therapeutics's own proxy. As printed: 2,404,692. Filing ↗ |
| 91 | Karyopharm Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-13 | 0001503802-26-000023 | CEO total compensation as printed in Karyopharm Therapeutics's own proxy. As printed: 2,320,902. Filing ↗machine: r2 · c29 · span 1192339–1192348 |
| 92 | Black Diamond Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001104659-26-051474 | CEO total compensation as printed in Black Diamond Therapeutics's own proxy. As printed: 2,234,919. Filing ↗machine: r1 · c41 · span 370031–370040 |
| 93 | Actuate Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-06 | 0001683168-26-002691 | CEO total compensation as printed in Actuate Therapeutics's own proxy. As printed: 2,166,522. Filing ↗machine: r1 · c19 · span 185828–185837 |
| 94 | Ironwood Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050325 | CEO total compensation as printed in Ironwood Pharmaceuticals's own proxy. As printed: 1,948,390. Filing ↗machine: t29 · r1 · c48 · span 584182–584191 |
| 95 | Collegium Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-07 | 0001628280-26-024063 | CEO total compensation as printed in Collegium Pharmaceuticals's own proxy. As printed: 1,715,846. Filing ↗machine: r2 · c48 · span 779394–779403 |
| 96 | Zentalis Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001725160-26-000027 | CEO total compensation as printed in Zentalis Pharmaceuticals's own proxy. As printed: 1,300,731. Filing ↗machine: r2 · c48 · span 319348–319357 |
| 97 | Section 10a, ACADIA Pharmaceuticals reciprocity | DEF 14A | — | 0001193125-26-174163 | ACADIA Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Coherus Oncology, Inc.. Filing ↗ |
| 98 | Section 10a, Collegium Pharmaceuticals reciprocity | DEF 14A | — | 0001628280-26-024063 | Collegium Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Coherus Oncology, Inc.. Filing ↗ |
| 99 | Section 10a, Agios Pharmaceuticals reciprocity | DEF 14A | — | 0001193125-26-177086 | Agios Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Coherus Oncology, Inc.. Filing ↗ |
| 100 | Section 10a, Deciphera Pharmaceuticals reciprocity | DEF 14A | — | 0001654151-24-000012 | Deciphera Pharmaceuticals names Coherus Oncology, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 101 | Section 10a, Amicus Pharmaceuticals reciprocity | DEF 14A | — | 0001140361-25-015479 | Amicus Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Coherus Oncology, Inc.. Filing ↗ |
| 102 | Section 10a, Puma Biotechnology reciprocity | DEF 14A | — | 0001437749-26-013671 | Puma Biotechnology names Coherus Oncology, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 103 | Section 10a, Eagle Pharmaceuticals reciprocity | DEF 14A | — | 0001104659-23-054338 | Eagle Pharmaceuticals names Coherus Oncology, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 104 | Section 10a, Heron Therapeutics reciprocity | DEF 14A | — | 0001193125-26-196306 | Heron Therapeutics names Coherus Oncology, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 105 | Section 10a, Mirum Pharmaceuticals reciprocity | DEF 14A | — | 0001759425-26-000027 | Mirum Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Coherus Oncology, Inc.. Filing ↗ |
| 106 | Section 10a, PTC Therapeutics reciprocity | DEF 14A | — | 0001104659-26-045528 | PTC Therapeutics's most recent proxy was read; its disclosed peer group does not include Coherus Oncology, Inc.. Filing ↗ |
| 107 | Section 10a, Olema Pharmaceuticals reciprocity | DEF 14A | — | 0001193125-26-191956 | Olema Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Coherus Oncology, Inc.. Filing ↗ |
| 108 | Section 10a, Precigen reciprocity | DEF 14A | — | 0001140361-26-018214 | Precigen's most recent proxy was read; its disclosed peer group does not include Coherus Oncology, Inc.. Filing ↗ |
| 109 | Section 10a, Perspective Therapeutics reciprocity | DEF 14A | — | 0001193125-26-159005 | Perspective Therapeutics's most recent proxy was read; its disclosed peer group does not include Coherus Oncology, Inc.. Filing ↗ |
| 110 | Section 10a, Cardiff Oncology reciprocity | DEF 14A | — | 0001213037-26-000006 | Cardiff Oncology's most recent proxy was read; its disclosed peer group does not include Coherus Oncology, Inc.. Filing ↗ |
| 111 | Section 10a, Xencor reciprocity | DEF 14A | — | 0001326732-26-000031 | Xencor's most recent proxy was read; its disclosed peer group does not include Coherus Oncology, Inc.. Filing ↗ |
| 112 | Section 10a, Pacira BioSciences reciprocity | DEF 14A | — | 0001104659-26-050353 | Pacira BioSciences's most recent proxy was read; its disclosed peer group does not include Coherus Oncology, Inc.. Filing ↗ |
| 113 | Section 10a, Pliant Therapeutics reciprocity | DEF 14A | — | 0001746473-26-000076 | Pliant Therapeutics's most recent proxy was read; its disclosed peer group does not include Coherus Oncology, Inc.. Filing ↗ |
| 114 | Section 10a, Supernus Pharmaceuticals reciprocity | DEF 14A | — | 0001104659-26-053111 | Supernus Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Coherus Oncology, Inc.. Filing ↗ |
| 115 | Section 10a, Nektar Therapeutics reciprocity | DEF 14A | — | 0001140361-26-016708 | Nektar Therapeutics's most recent proxy was read; its disclosed peer group does not include Coherus Oncology, Inc.. Filing ↗ |
| 116 | Section 10a, Allogene Therapeutics reciprocity | DEF 14A | — | 0001628280-26-028948 | Allogene Therapeutics's most recent proxy was read; its disclosed peer group does not include Coherus Oncology, Inc.. Filing ↗ |